Sarah Cannon Research Institute | Strategic Alliance Partners

February 06, 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.

February 05, 2019

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the promise of T-DM1 in the treatment of patients with HER2-positive breast cancer.

February 03, 2019

Denise A. Yardley, MD, discusses key data presented at the 2018 SABCS and the impact of the SOLAR-1 findings.

February 02, 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

February 01, 2019

Howard A. “Skip” Burris, MD, highlights some of the exciting updates from the 2018 San Antonio Breast Cancer Symposium and what can be expected in the breast cancer field in the year ahead.

February 01, 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.

January 31, 2019

Stephanie L. Graff, MD, discusses the latest updates on escalation and de-escalation of therapy in patients with HR-positive breast cancer.

January 28, 2019

Erika P. Hamilton, MD, discusses the findings from the phase II nextMONARCH 1 study of abemaciclib in HR-positive, HER2-negative advanced breast cancer.

January 24, 2019

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

December 17, 2018

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the addition of biosimilars to breast oncology.

October 16, 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

October 05, 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

September 25, 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

September 21, 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

September 19, 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

September 15, 2018

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the RESPECT trial in HER2-positive breast cancer.

September 07, 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

August 29, 2018

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

August 28, 2018

Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.

August 27, 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses data with talazoparib in breast cancer.